page not found « sucampo  aboutmission vision  valueshistorycommunitymanagementboardlocationsscience  innovationpipelineregister as an investigative siteproductunited statesasiaeuropemenu iteminvestorspartneringour partnerspartnership opportunitiesnewscareerscareer opportunities  aboutaboutaboutmission vision  valueshistorycommunitymanagement oldboardlocationsscience  innovationscience  innovationscience  innovationpipelineregister as an investigative siteproductproductproducteuropeasiaunited statesinvestorsinvestorsinvestorsfinancials  sec filingsanalyst coveragestock informationevents  presentationscorporate governanceonline investor centerpartneringpartneringpartneringour partnerspartnership opportunitiesnewscareerscareerscareerscareer opportunitiesth december sucampo appoints john h johnson to board of directorsfiled under uncategorised — djm   ambethesda md december   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced the appointment of john h johnson founder plum brook advisors to its board of directors board “we are pleased to welcome john to our board during sucampo’s continued evolution” said peter greenleaf chief executive officer of sucampo “as a recognized leader in the biopharmaceutical industry who has tremendous experience in building and growing sciencefocused companies john will be instrumental as we continue to execute on our strategic objectives accelerate the development of our pipeline and diversify our science” mr johnson brings more than  years of leadership experience in the pharmaceutical and biotechnology industry to sucampo he has held executive management roles at leading global corporations including johnson  johnson eli lilly  company imclone and pfizer inc he recently served as a member of the board of directors of pharmaceutical research and manufacturers of america phrma and as a member of the health section governing board of biotechnology industry organization bio he also served as chairman president and chief executive officer of dendreon corporation and as chief executive officer and board member of savient pharmaceuticals inc prior to these roles mr johnson served as president of eli lilly  company’s oncology unit following its  acquisition of imclone systems inc where he served as chief executive officer and board member before joining imclone he held various executive roles of increasing responsibility including company group chairman of biopharmaceuticals at johnson  johnson where he was responsible for the johnson  johnson biotechnology immunology and oncology commercial businesses earlier in his career mr johnson held multiple executive positions at parkstone medical information systems inc orthomcneil pharmaceutical corp and pfizer inc mr johnson served as the chairman of tranzyme pharma inc and as a member of the board of bionj mr johnson currently serves as a member of the board of directors of cempra pharmaceuticals inc histogenics and portola pharmaceuticals “i am excited about the opportunity to join sucampo’s board of directors and leadership team” said john h johnson “i look forward to contributing to sucampo’s future growth and success developing and diversifying its pipeline and its delivery to patients in need and healthcare providers around the world” about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected compare hotels sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent forms k and k which sucampo incorporates by reference contact sucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom comments th november sucampo pharmaceuticals announces webcast of its presentation at the th annual piper jaffray healthcare conferencefiled under uncategorised — djm   ambethesda md november   globe newswire – sucampo pharmaceuticals inc sucampo nasdaqscmp a global biopharmaceutical company today announced that it will webcast its corporate presentation at the th annual piper jaffray healthcare conference taking place tuesday december   at  am etthe presentation will be webcast live and may be accessed from the event calendar page of sucampo’s website at investorsucampocom  presentation slides will be available via the webcast links a replay of the webcast will also be available on the company’s website for several days after the live event to ensure a timely connection it is recommended that users register at least  minutes prior to the scheduled webcast about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected satellite pictures sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom comments th november sucampo files patent infringement lawsuit against dr reddy’sfiled under uncategorised — djm   ambethesda md november   globe newswire – sucampo pharmaceuticals inc nasdaq scmp a global biopharmaceutical company today announced that sucampo rtech ueno ltd takeda pharmaceutical company limited takeda and certain affiliates of takeda have filed a patent infringement lawsuit in the united states district court for the district of new jersey against dr reddy’s laboratories ltd and dr reddy’s laboratories inc collectively dr reddy’s related to an abbreviated new drug application anda that dr reddy’s filed with the us food and drug administration fda to market sell and use a generic version of the  mcg and  mcg amitiza® lubiprostone soft gelatin capsule products the lawsuit claims infringement of  patents that are listed in the fda’s orange book with the latest expiring in  sucampo commenced the lawsuit within  days from the receipt of a notice letter sent by dr reddy’s dated october   regarding its filing of its anda under the hatchwaxman act as a result of the patent infringement lawsuit final fda approval of dr reddy’s anda will be stayed up to  months from the date of receipt of the notice letter “protecting amitiza’s intellectual property is of paramount importance to sucampo” said peter greenleaf chief executive officer of sucampo “we believe that the amitiza patents granted by the us patent  trademark office are valid enforceable and infringed by dr reddy’s proposed lubiprostone products and we will vigorously defend them” about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom   comments th november sucampo pharmaceuticals announces webcast of its presentation at the stifel  healthcare conferencefiled under uncategorised — djm   ambethesda md november   globe newswire – sucampo pharmaceuticals inc sucampo nasdaqscmp a global biopharmaceutical company today announced that it will webcast its corporate presentation at the stifel  healthcare conference taking place tuesday november   at  pm etthe presentation will be webcast live and may be accessed from the event calendar page of sucampo’s website at httpinvestorsucampocomphoenixzhtmlcpirolcalendar presentation slides will be available via the webcast links a replay of the webcast will also be available on the company’s website for several days after the live event to ensure a timely connection it is recommended that users register at least  minutes prior to the scheduled webcast about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom comments th november sucampo announces third quarter  financial resultsfiled under uncategorised — djm   amstrong revenue and sales growth for amitiza® raises  earnings guidance excluding special items ceo peter greenleaf to provide update on significant progress against strategic plan sucampo to host conference call today at  am eastern bethesda md november   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp today reported consolidated financial results for the third quarter and nine months ended september   sucampo reported year over year growth of  to  million in total revenue  to  million in product royalty revenue and  to  million in product sales sucampo also reported net income of  million and fullydiluted earnings per share eps of  during the third quarter of  sucampo raised its full year  earnings guidance to  million to  million net income excluding special items versus previous guidance of  million to  million during the third quarter of  sucampo recorded a noncash impairment to its intangible assets of  million to reflect a reduction in the expected future cash flows received from the sales of rescula for the approved indication which sucampo has ceased marketing and no further orders have been made details of the impairment charge are discussed in the cost of goods and rd expenses sections below sucampo is providing certain  nongaap information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends management believes that providing this information enhances investors’ understanding of sucampo’s performance this information should be considered in addition to but not in lieu of information prepared in accordance with gaapnet income is attributable to sucampo pharmaceuticals inc on a consolidated basis “in the third quarter sucampo’s strong financial performance continued and i am pleased that we made significant progress against our strategy” said peter greenleaf chief executive officer of sucampo “our total revenue grew  driven by amitiza’s continued growth in the us and japan the prospects for additional growth of the product are greater than ever given the agreements we signed this quarter creating a global partnership with takeda expanding the current amitiza agreement with takeda for north america and settling our generic litigation this is a time of great opportunity for sucampo as we continue to execute on our strategy with a focus on the development of our pipeline and the diversification of our science”   third quarter  operational review amitizaunited states us amitiza® lubiprostone total prescriptions were  an increase of  compared to the third quarter of  net sales of amitiza reported by takeda pharmaceuticals usa inc takeda for royalty calculation purposes increased  to  million for the third quarter of  compared to  million in the same period of  net sales of amitiza reported by takeda for royalty calculation purposes increased  to  million for the first nine months of  compared to  million in the same period of  launched a pilot directtoconsumer dtc advertising campaign with takeda in select us markets for amitiza sucampo takeda and rtech ueno ltd rtu entered into a settlement and license agreement with anchen pharmaceuticals inc par pharmaceutical inc and par pharmaceutical companies inc that resolved patent litigation among the parties related to amitiza  mcg and  mcg soft gelatin capsules signed an extension to our existing collaboration and license agreement with takeda covering the us and canada for amitiza global markets in japan sucampo’s revenue from sales of amitiza to abbott japan co ltd abbott for the third quarter of  was  million an increase of  million compared to the same period of  sucampo’s revenue from sales of amitiza to abbott for the first nine months of  was  million an increase of  million compared to the same period of  sucampo also announced that it had earned a  million milestone payment from abbott pursuant to the existing license commercialization and supply agreement the milestone payment was triggered by the first occurrence of annual net sales of lubiprostone for chronic idiopathic constipation cic in japan exceeding jpy  billion entered into a global license development commercialization and supply agreement for amitiza with takeda which expanded takeda’s exclusive rights to all global markets except japan and the people’s republic of china signed an exclusive global manufacturing and supply agreement with rtu for clinical and commercial supplies of amitiza in most global markets in the european union eu the mutual recognition procedure mrp started on october st to obtain approval in additional eu countries for amitiza for cic the mrp is anticipated to be completed in the first half of  in canada sucampo filed amitiza for the cic and opioidinduced constipation oic indications with health canada a decision is anticipated in the second half of  research and development in october four abstracts on lubiprostone were presented at the american college of gastroenterology  annual scientific meeting   corporate peter kiener d phil was appointed chief scientific officer matthias alder was appointed executive vice president business development  licensing steven caffé md was appointed senior vice president regulatory affairs cary claiborne chief financial officer cfo will leave sucampo on november  a search for a new cfo is ongoing third quarter  financial review net income was  million or  per diluted share for the third quarter of  compared to a net income of  million or  per diluted share in the same period in  net income was  million or  per diluted share for the first nine months of  compared to a net income of  million or  per diluted share in the same period in  total revenues were  million for the third quarter of  compared to  million in the same period in  an increase of  total revenues were  million for the first nine months of  compared to  million in the same period in  an increase of  the increase for both periods was primarily due to higher royalty revenue on amitiza net sales in the us and the growth of amitiza sales in japan as well as a  million milestone earned in japan the increase for the nine months in  royalty revenues and product sales from the same period in  were offset by the  receipt of the  million milestone payment from takeda upon the first commercial sale of amitiza for oic costs of goods sold were  million for the third quarter of  compared to  million for the same period of  a decrease of  the decrease was primarily due to a  million noncash writeoff of rescula inventory in the prior year period which did not reoccur partially offset by higher product purchases expenses as a result of increased volume of amitiza sales in japan costs of goods sold were  million for the first nine months of  compared to  million for the same period of  an increase of  the increase for the nine months was primarily due to increased volume of amitiza sales in japan partially offset by the  million noncash writeoff of rescula inventory in the prior year which did not reoccur intangible assets impairment was  million for the third quarter of  compared to nil for the same period of  the noncash impairment reflects a reduction in the expected future cash flows received from the sales of rescula in the fda approved indication which is no longer marketed and for which no orders have been placed for additional inventory rd expenses were  million for the third quarter of  compared to  million for the same period of  an increase of  rd expenses were  million for the first nine months of  compared to  million for the same period of  an increase of  the increase for both periods was primarily due to increased costs of our lubiprostone pediatric trial ga expenses were  million for the third quarter of  compared to  million for the same period of  an increase of  ga expenses were  million for the first nine months of  compared to  million for the same period of  an increase of  the increase for both periods was primarily due to a significant increase in legal fees incurred prosecuting a patent infringement lawsuit filed by us in february  the increase for the nine months was partially offset by a reduction in pharmacovigilance costs that were associated with launching amitiza in japan in  selling  marketing expenses were  million for the third quarter of  compared to  million for the same period of  a decrease of  selling  marketing expenses were  million for the first nine months of  compared to  million for the same period of  a decrease of  the decrease for both periods was primarily due to the replacement of our inhouse sales force with a lowercost contract sales force in  and a  million noncash writeoff of rescula in samples in the prior year that did not reoccur this year the decrease for the first nine months of  was partially offset by increased commercialization costs in europe for amitiza earnings excluding special items net income excluding special items for the third quarter of  was  million or  per diluted share compared to a net income of  million or  per diluted share in the third quarter of  net income excluding special items for the first nine months of  was  million or  per diluted share compared to a net income of  million or  per diluted share in the first nine months of  nongaap generally accepted accounting principles eps for the third quarter and nine months ended september   of  and  respectively exclude rescula intangible impairment a reconciliation of gaap to nongaap net income and eps is provided in the tables that follow represents the difference between calculated gaap eps and calculated nongaap eps which may be different than the amount calculated by dividing the impact of the excluded items by the weightedaverage shares for the period cash cash equivalents restricted cash and marketable securities at september   cash cash equivalents restricted cash and investments were  million compared to  million at december   at september   notes payable were  million compared to  million at december   including current notes payable of  million at september   and  million at december   guidance sucampo today increased its earnings guidance for  sucampo now expects full year  gaap net income excluding special items to be in the range of  million to  million or  to  per diluted share   company to host conference call today sucampo will host a conference call and webcast today at  am eastern to participate on the live call please dial  domestic or  international and provide the participant passcode  five to ten minutes ahead of the start of the call a replay of the call will be available within a few hours after the call ends investors may listen to the replay by dialing  domestic or  international passcode  investors interested in accessing the live audio webcast of the teleconference may do so at httpinvestorsucampocom and should log on before the teleconference begins in order to download any software required the archive of the teleconference will remain available for  daysabout lubiprostone amitiza® amitiza lubiprostone is a prostone and is a locally acting chloride channel activator indicated in the us for the treatment of cic in adults and oic in adults with chronic noncancer pain  mcg twice daily the effectiveness in patients with oic taking diphenylheptane opioids eg methadone has not been established amitiza is also indicated in the us for irritable bowel syndrome with constipation  mcg twice daily in women  years of age and older in japan amitiza  mcg twice daily is indicated for the treatment of chronic constipation excluding constipation caused by organic diseases in the united kingdom uk amitiza  mcg twice daily is indicated for the treatment of cic and associated symptoms in adults when response to diet and other nonpharmacological measures eg educational measures physical activity are inappropriate in switzerland amitiza  mcg twice daily is indicated for the treatment of cic in adults and for the treatment of oic and associated signs and symptoms such as stool consistency straining constipation severity abdominal discomfort and abdominal bloating in adults with chronic noncancer pain the efficacy of amitiza for the treatment of oic in patients taking opioids of the diphenylheptane class such as methadone has not been established about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the uk for more information please visit wwwsucampocom the sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation the ability of sucampo to develop and commercialize existing and pipeline products sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally the effects of competitive products on sucampo’s products and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k as filed with the securities and exchange commission on march   as well as its filings with the securities and exchange commission on form q and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom comments th november sucampo pharmaceuticals announces webcast of its presentation at the  credit suisse global healthcare conferencefiled under uncategorised — djm   ambethesda md november   globe newswire – sucampo pharmaceuticals inc sucampo nasdaqscmp a global biopharmaceutical company today announced that it will webcast its corporate presentation at the  credit suisse global healthcare conference taking place wednesday november   at  pm mountain time or  pm eastern timethe presentation will be webcast live and may be accessed from the event calendar page of sucampo’s website at httpinvestorsucampocomphoenixzhtmlcpirolcalendar presentation slides will be available via the webcast links a replay of the webcast will also be available on the company’s website for several days after the live event to ensure a timely connection it is recommended that users register at least  minutes prior to the scheduled webcast about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation the ability of sucampo to develop and commercialize existing and pipeline products sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k as filed with the securities and exchange commission on march   as well as its filings with the securities and exchange commission on form q and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom    comments th october sucampo pharmaceuticals inc announces third quarter  earnings callfiled under uncategorised — djm   ambethesda md october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced that it will host its third quarter  financial results teleconference and webcast at  am eastern on thursday november   the press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day individuals interested in accessing the live audio webcast of the teleconference may do so at httpinvestorsucampocomphoenixzhtmlcpirolcalendar and should log on  to  minutes before the teleconference begins to download any software required presentation slides will be available via the webcast link a replay of the webcast will also be available on sucampo’s website for several days after the live event alternatively individuals may dial  domestic or  international and use passcode  a replay of the teleconference will be available by dialing  domestic or  international passcode  approximately two hours after the teleconference concludes the archive of the teleconference will be available for  days about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation the ability of sucampo to develop and commercialize existing and pipeline products sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k as filed with the securities and exchange commission on march   as well as its filings with the securities and exchange commission on form q and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom  comments rd october sucampo solidifies leadership team with additions of cso and heads of business development regulatory affairsfiled under uncategorised — djm   ambethesda md october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced three executive appointments that expand and solidify the leadership team in line with the company’s strategic plan the appointments are peter kiener dphil             as chief scientific officer cso matthias alder as executive vice president business development and licensing and steven caffé md as senior vice president regulatory affairs “we are building a stronger focused company and filling our key leadership roles with these highcaliber executives is essential for sucampo’s continued evolution” said peter greenleaf chief executive officer of sucampo “the addition of tenured biopharmaceutical executives gives us the depth of scientific leadership to expedite our company’s transformation and to execute on our priorities of leveraging sucampo’s strengths in drug development securing and growing revenue from sales of amitiza increasing our pace of current pipeline development and diversifying our portfolio through the acquisition of new science each of the new executives brings to sucampo functional expertise and a track record of success and each of them sees as i do the potential of our strategic vision for sucampo” dr kiener is recognized for his expertise in the development of nextgeneration biologics most recently he was cso of ambrx inc a clinicalstage biopharmaceutical company focused on the development of antibodydrug conjugates prior to joining ambrx dr kiener was president and cofounder of zyngenia inc an early stage biopharmaceutical company before this he was executive vice president and global head of biologics research and development at medimmune llc the global biologics arm of astrazeneca during his tenure there dr kiener assisted with building the company’s industryleading protein and antibody engineering capabilities and oversaw the submission of multiple investigational new drug and new drug applications earlier in his career he held multiple positions at bristolmyers squibb over an year period where he worked on biologics dr kiener has served on the scientific advisory boards of kai pharmaceuticals inc genocea biosciences inc nkt therapeutics inc and vlst corporation dr kiener has also served as a director of receptor biologix inc synovex corporation and virdante pharmaceuticals inc he received his bachelor’s degree in chemistry from the university of lancaster and doctorate of philosophy in biochemistry from the university of oxford dr kiener has published more than  papers in peerreviewed journals and is an inventor on more than  patents and patent applications mr alder brings more than  years of industry experience to sucampo most recently he was executive vice president of corporate development and legal affairs and corporate secretary at cytos biotechnology ag a biopharmaceutical company focused on the development of targeted immunotherapies prior to joining cytos he held various roles of increasing responsibility including senior vice president administration general counsel and secretary of micromet inc which was acquired by amgen prior to this mr alder was a partner in the life sciences transactions practice at cooley llp where he represented biotech companies in strategic transactions with pharmaceutical companies earlier in his career mr alder was inhouse counsel at cibageigy and novartis he holds law degrees from the university of basel and the university of miami and is qualified to practice law in switzerland and the us dr caffé brings more than  years of global product development registration and lifecycle management expertise to the company prior to joining sucampo he was senior vice president and chief development and regulatory officer at amag pharmaceuticals inc a specialty pharmaceutical company where he played a key role in the provision of strategic insight and operational expertise to ensure successful product development and advancement and in the acquisition of assets prior to joining amag dr caffé was senior vice president head of global regulatory affairs and patient safety at medimmune at medimmune he was responsible for all regulatory and pharmacovigilance matters for commercial and pipeline products prior to this he held increasing leadership positions at baxter international inc sanofi and merck  co through various regulatory and development programs he secured product approvals while building and leading highperforming global teams dr caffé received his medical degree from the faculté de médecine saintantoine université pierre et marie curie paris  and completed his internship and residency and practiced medicine at the academic hospitals of the assistance publique de paris with a focus on emergency and intensive care about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the uk for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom comments st october takeda and sucampo enter into global licensing agreement for amitiza® lubiprostonefiled under uncategorised — djm   amtakeda gains exclusive rights to amitiza beyond us and canada for all markets except japan and china  bethesda md october   and osaka japan october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company and takeda pharmaceutical company limited takeda today announced that on october   they entered into a global license development commercialization and supply agreement for amitiza® lubiprostone through this agreement takeda expanded its exclusive rights beyond the united states us and canada to further develop and commercialize amitiza in all global markets except japan and the people’s republic of china “takeda is committed to being a patient and customercentric organization making quality health products available to the patients who need them through this agreement amitiza can now be made available to patients worldwide” said shinji honda senior managing director and corporate strategy officer “takeda forms partnerships to advance science and to provide innovative treatment options for patients and this global agreement is an excellent example this global collaboration leverages the expertise we have established through our gastroenterology portfolio of products” “the expansion of our collaboration with takeda represents a critical step forward with our strategic plan and is the natural evolution of our partnership with them for north america” said peter greenleaf chief executive officer of sucampo “this agreement allows sucampo to remain focused on our strengths in drug development while allowing us to make amitiza available to more patients in need around the world we are confident that with the combination of their extensive experience with amitiza and proven global infrastructure that takeda will build the brand in new global markets as they have done in the us where amitiza continues to grow steadily” under the terms of the agreement sucampo will receive an upfront payment of  million from takeda and will also be eligible for up to  million in additional commercial milestones contingent on the achievement of certain net sales revenue targets additionally sucampo will be the exclusive supplier of amitiza to takeda at an agreedupon supply price takeda will be responsible for all development activities and costs with sucampo assuming responsibility for the first  million in development expenses in addition takeda will become the marketing authorization holder and will be responsible for all commercialization and regulatory activities about amitiza lubiprostone amitiza lubiprostone is a prostone and is a locally acting chloride channel activator indicated in the united states for the treatment of chronic idiopathic constipation cic in adults and opioidinduced constipation oic in adults with chronic noncancer pain  mcg twice daily the effectiveness in patients with oic taking diphenylheptane opioids eg methadone has not been established amitiza is also indicated in the us for irritable bowel syndrome with constipation ibsc  mcg twice daily in women  years of age and older important safety informationamitiza lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider hcp to confirm the absence of such an obstruction prior to initiating amitiza treatment patients taking amitiza may experience nausea if this occurs concomitant administration of food with amitiza may reduce symptoms of nausea patients who experience severe nausea should inform their hcp amitiza should not be prescribed to patients that have severe diarrhea patients should be aware of the possible occurrence of diarrhea during treatment patients should be instructed to discontinue amitiza and inform their hcp if severe diarrhea occurs patients taking amitiza may experience dyspnea within an hour of first dose this symptom generally resolves within three hours but may recur with repeat dosing patients who experience dyspnea should inform their hcp some patients have discontinued therapy because of dyspnea in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with cic the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  headache  vs  abdominal pain  vs  abdominal distension  vs  and flatulence  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with oic the most common adverse reactions incidence  were nausea  vs  and diarrhea  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with ibsc the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  and abdominal pain  vs  concomitant use of diphenylheptane opioids eg methadone may interfere with the efficacy of amitiza the safety of amitiza in pregnancy has not been evaluated in humans based on animal data amitiza may cause fetal harm amitiza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus caution should be exercised when amitiza is administered to a nursing woman advise nursing women to monitor infants for diarrhea reduce the dosage in cic and oic patients with moderate and severe hepatic impairment reduce the dosage in ibsc patients with severe hepatic impairment please see the full prescribing information here for further information on amitiza please visit wwwsucampocomproducts about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocom the sucampo logo is the registered trademark and the tagline the science of innovation is a pending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation the ability of sucampo to develop and commercialize existing and pipeline products sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally the effects of competitive products on sucampo’s products and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k as filed with the securities and exchange commission on march   as well as its filings with the securities and exchange commission on form q and k which sucampo incorporates by reference about takeda pharmaceutical company limited located in osaka japan takeda is a researchbased global company with its main focus on pharmaceuticals as the largest pharmaceutical company in japan and one of the global leaders of the industry takeda is committed to strive towards better health for people worldwide through leading innovation in medicine additional information about takeda is available through its corporate website wwwtakedacom takeda forwardlooking statement this press release contains forwardlooking statements forwardlooking statements include statements regarding takeda’s plans outlook strategies results for the future and other statements that are not descriptions of historical facts forwardlooking statements may be identified by the use of forwardlooking words such as “may” “believe” “will” “expect” “project” “estimate” “should” “anticipate” “plan” “assume” “continue” “seek” “pro forma” “potential” “target” “forecast” “guidance” “outlook” or “intend” or other similar words or expressions of the negative thereof forwardlooking statements are based on estimates and assumptions made by management that are believed to be reasonable though they are inherently uncertain and difficult to predict investors are cautioned not to unduly rely on such forwardlooking statements forwardlooking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forwardlooking statements some of these risks and uncertainties include but are not limited to  the economic circumstances surrounding takeda’s business including general economic conditions in japan the us and worldwide  competitive pressures and developments  applicable laws and regulations  the success or failure of product development programs  actions of regulatory authorities and the timing thereof  changes in exchange rates  claims or concerns regarding the safety or efficacy of marketed products or product candidates in development and  integration activities with acquired companies the forwardlooking statements contained in this press release speak only as of the date of this press release and takeda undertakes no obligation to revise or update any forwardlooking statements to reflect new information future events or circumstances after the date of the forwardlooking statement if takeda does update or correct one or more of these statements investors and others should not conclude that takeda will make additional updates or corrections contact sucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom takeda pharmaceutical company limitedcorporate communications depttel  takeda pharmaceuticals international incjocelyn gerstcorporate communications depttel  comments th october clinical data for amitiza® lubiprostone to be presented at the american college of gastroenterology  annual scientific meetingfiled under uncategorised — djm   ambethesda md october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced that clinical data for amitiza® lubiprostone will be presented at the american college of gastroenterology acg  annual scientific meeting on sunday october  and monday october  at the pennsylvania convention center in philadelphia poster presentations the following abstracts will be presented at acg  sunday oct  from  pm to  pm edtweek  response predicts durable response to lubiprostone in patients with chronic idiopathic constipation ayesha akbar mbchb hons mrcp phd taryn loschberidon bs martin wang ms peter lichtlen md phdposter no p impact of methadone dose and baseline bowel movement frequency on efficacy of lubiprostone for opioidinduced constipation byron cryer md peter lichtlen md phd martin wang ms taryn loschberidon bsposter no pmonday oct  from  am to  pm edteffects of lubiprostone in patients with chronic idiopathic and opioidinduced constipation on serum electrolytes and markers of renal function satish s c rao md phd facg egilius l h spierings md phd john f johanson md msc facp facg peter lichtlen md phd sepideh habibi mdposter no p lubiprostone for treatment of opioidinduced constipation analysis of influencing factors taryn loschberidon bs peter lichtlen md phd martin wang msposter no p about amitiza lubiprostone amitiza lubiprostone is a prostone and is a locally acting chloride channel activator indicated in the united states for the treatment of chronic idiopathic constipation cic in adults and opioidinduced constipation oic in adults with chronic noncancer pain  mcg twice daily the effectiveness in patients with oic taking diphenylheptane opioids eg methadone has not been established amitiza is also indicated in the us for irritable bowel syndrome with constipation ibsc  mcg twice daily in women  years of age and older important safety informationamitiza lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider hcp to confirm the absence of such an obstruction prior to initiating amitiza treatment patients taking amitiza may experience nausea if this occurs concomitant administration of food with amitiza may reduce symptoms of nausea patients who experience severe nausea should inform their hcp amitiza should not be prescribed to patients that have severe diarrhea patients should be aware of the possible occurrence of diarrhea during treatment patients should be instructed to discontinue amitiza and inform their hcp if severe diarrhea occurs patients taking amitiza may experience dyspnea within an hour of first dose this symptom generally resolves within three hours but may recur with repeat dosing patients who experience dyspnea should inform their hcp some patients have discontinued therapy because of dyspnea in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with cic the most common adverse reactions incidence   were nausea  vs  diarrhea  vs   headache  vs  abdominal pain  vs  abdominal distension  vs  and flatulence  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n in patients with oic the most common adverse reactions incidence   were nausea  vs  and diarrhea  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with ibsc the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  and abdominal pain  vs  concomitant use of diphenylheptane opioids eg methadone may interfere with the efficacy of amitiza the safety of amitiza in pregnancy has not been evaluated in humans based on animal data amitiza may cause fetal harm amitiza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus caution should be exercised when amitiza is administered to a nursing woman advise nursing women to monitor infants for diarrhea reduce the dosage in cic and oic patients with moderate and severe hepatic impairment reduce the dosage in ibsc patients with severe hepatic impairment please see the full prescribing information here for further information on amitiza please visit wwwsucampocomproducts about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines to meet the major unmet medical needs of patients on a global basis sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the uk for more information please visit wwwsucampocom the sucampo logo is the registered trademark and the tagline the science of innovation is a pending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom  comments th october sucampo announces extension of amitiza® lubiprostone license and collaboration agreement with takedafiled under uncategorised — djm   ambethesda md october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced that it signed on october   an amendment to the existing collaboration and license agreement collaboration agreement covering the united states us and canada for amitiza® lubiprostone with takeda pharmaceutical company ltd takeda the amendment includes various modifications to the collaboration agreement including the extension of the current term minimum commercial investment during the current term and various governance changes allowing takeda additional flexibility in commercializing amitiza during the extended term which will begin on january   takeda will split with sucampo the gross profits of branded amitiza for any dosage strength and form for the existing indications in the us and canada in addition on april   takeda will no longer reimburse sucampo for the product details made by sucampo sales representatives to healthcare professionals as well as other ancillary costs of the sales force “today’s announcement of the extended collaboration with takeda is yet another step toward achieving our objective of securing sucampo’s foundation and expanding the amitiza business this extended collaboration also allows sucampo to share in the longterm value of amitiza” said peter greenleaf chief executive officer of sucampo “takeda and sucampo are aligned in our objectives for the brand and i believe this newly extended collaboration and license agreement positions the companies more strongly than ever to help grow the amitiza business”  about amitiza lubiprostone amitiza lubiprostone is a prostone and is a locally acting chloride channel activator indicated in the us for the treatment of chronic idiopathic constipation cic in adults and opioidinduced constipation oic in adults with chronic noncancer pain  mcg twice daily the effectiveness in patients with oic taking diphenylheptane opioids eg methadone has not been established amitiza is also indicated in the us for irritable bowel syndrome with constipation ibsc  mcg twice daily in women  years of age and older important safety informationamitiza lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider hcp to confirm the absence of such an obstruction prior to initiating amitiza treatment patients taking amitiza may experience nausea if this occurs concomitant administration of food with amitiza may reduce symptoms of nausea patients who experience severe nausea should inform their hcp amitiza should not be prescribed to patients that have severe diarrhea patients should be aware of the possible occurrence of diarrhea during treatment patients should be instructed to discontinue amitiza and inform their hcp if severe diarrhea occurs patients taking amitiza may experience dyspnea within an hour of first dose this symptom generally resolves within three hours but may recur with repeat dosing patients who experience dyspnea should inform their hcp some patients have discontinued therapy because of dyspnea in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with cic the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  headache  vs  abdominal pain  vs  abdominal distension  vs  and flatulence  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with oic the most common adverse reactions incidence  were nausea  vs  and diarrhea  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with ibsc the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  and abdominal pain  vs  concomitant use of diphenylheptane opioids eg methadone may interfere with the efficacy of amitiza the safety of amitiza in pregnancy has not been evaluated in humans based on animal data amitiza may cause fetal harm amitiza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus caution should be exercised when amitiza is administered to a nursing woman advise nursing women to monitor infants for diarrhea reduce the dosage in cic and oic patients with moderate and severe hepatic impairment reduce the dosage in ibsc patients with severe hepatic impairment please see the full prescribing information here for further information on amitiza please visit wwwsucampocomproducts about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the uk for more information please visit wwwsucampocom the sucampo logo is the registered trademark and the tagline the science of innovation is a pending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom  comments th october sucampo announces settlement agreement that resolves patent litigation in us related to amitizafiled under uncategorised — djm   amcompany receives additional paragraph iv notice bethesda maryland october   globe newswire — sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced that sucampo rtech ueno ltd rtu takeda pharmaceutical company limited takeda and certain affiliates of takeda have entered into a settlement and license agreement with anchen pharmaceuticals inc par pharmaceutical inc and par pharmaceutical companies inc collectively par that resolves patent litigation in the united states us related to sucampo’s amitiza® lubiprostone  mcg and  mcg soft gelatin capsules under the terms of the settlement sucampo and rtu will grant par a nonexclusive license to market par’s generic version of lubiprostone  mcg soft gelatin capsule and  mcg soft gelatin capsule licensed products in the us for the indications approved for amitiza beginning january   or earlier under certain circumstances beginning on january   par will split with sucampo the gross profits of the licensed products sold during the term of the agreement which continues until each of the sucampo patents has expired in the event par elects to launch an authorized generic sucampo will supply par under the terms of a manufacturing and supply agreement at a negotiated price additional details of the agreement remain confidential “this settlement agreement is an important step for sucampo toward securing our foundation and continuing to grow sales of amitiza” said peter greenleaf chief executive officer of sucampo “we are on track with the strategic imperatives i communicated in august that include a sharp focus on our flagship product this is not only beneficial to our company and shareholders it is important to prescribing physicians and their patients who depend on amitiza for treatment” sucampo rtu takeda and par have agreed to dismiss with prejudice the patent litigation filed in the us district court for the district of delaware additionally sucampo said it has received a paragraph iv certification notice letter notice letter regarding an abbreviated new drug application anda submitted to the us food and drug administration fda by dr reddy’s laboratories inc dr reddy’s requesting approval to market sell and use a generic version of the  mcg and  mcg amitiza® lubiprostone soft gelatin capsule products sucampo is currently reviewing the notice letter by statute if sucampo initiates a patent infringement lawsuit against dr reddy’s within  days of the notice date the fda would automatically stay approval of the dr reddy’s anda until the earlier of  months from the notice date or entry of a district court decision finding the patents invalid or not infringed the product is currently protected by  issued patents that are listed in the fda’s orange book with the latest expiring in  “we will continue to vigorously enforce amitiza’s intellectual property rights” said greenleaf “generic companies have made paragraph iv certifications a routine part of business sucampo is well prepared to pursue all legal pathways in defense of amitiza” about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a pending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom comments contact us tel sucampo pharmaceuticals inc  king farm boulevard suite  rockville maryland infosucampocom  sucampo pharmaceuticals inc is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza its lead product and rescula – and a latestage pipeline of product candidates in clinical development for orphan disease areas vts is a mixture of hydroxypropylbcyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the us and europe and is in a pivotal phase  clinical trial for the treatment of niemannpick disease type c sucampo has an option for the north american rights to cpp xsulindac which is in phase  development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the us a global company sucampo is headquartered in rockville maryland and has operations in japan and switzerland access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id eefaecdcdf powered by perimeterx  inc access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id edbfaeddef powered by perimeterx  inc access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id eadaedbcae powered by perimeterx  inc ambrx appoints peter kiener phd as chief scientific officer ambrx appoints peter kiener phd as chief scientific officer experienced leader brings decades of expertise in development of nextgeneration biologic therapeutics aug    et from ambrx san diego aug   prnewswire  ambrx today announced the appointment of peter kiener phd as chief scientific officer dr kiener brings decades of expertise in the development of nextgeneration biologic therapeutics including multispecific antibody based biologics while president chief executive officer and cofounder of zyngenia dr kiener has an impressive track record of working with cuttingedge technologies and the addition of his expertise will help ambrx further advance its pipeline of antibody drug conjugate adc and bispecific antibody therapeutics said lawson macartney phd chief executive officer of ambrx we aim to capitalize on the momentum gained from the four partnerships weve formed in the past year to grow our internal pipeline while also continuing our streak of dealmaking activities for our nextgeneration technology added dr kiener based on my review of the companys data and ongoing collaborations ambrxs protein medicinal chemistry platform technology has shown its vast potential for the development of bestinclass adcs and bispecific antibodies i look forward to advancing the technology and supporting ongoing partnership activities as interest in the space continues to grow as cofounder of zyngenia dr kiener led the company through its early stages of development including validating the technology platform identifying and advancing lead programs as well as securing series a funding prior to cofounding zyngenia dr kiener was the executive vice president and global head of biologics research and development at medimmune astrazenecas biologics arm in this role he built industry leading protein and antibody engineering capabilities as well as oversaw the submission of multiple inds and ndas prior to medimmune dr kiener held multiple positions at bristolmyers squibb over an  year tenure ten years of which were spent working on biological therapeutics dr kiener has published more than  papers in peerreviewed journals and is an inventor on more than  patents and patent applications he holds a bachelors degree in chemistry from the university of lancaster and a doctorate of philosophy from the university of oxford about ambrx ambrx inc is a clinical stage biopharmaceutical company using an expanded genetic code to create bestinclass biotherapeutics including adcs bispecific antibodies and proteins with improved pharmacologic properties the company is developing arx a longacting growth hormone that has successfully completed phase b clinical trials in addition to its most recent adc collaborations with merck astellas bristolmyers squibb and zhejiang medicine co ltd zmc ambrx has collaborations to discover and develop products incorporating ambrx technology with bristolmyers squibb eli lilly and several undisclosed companies ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy safety and ease of use in multiple therapeutic areas for additional information visit wwwambrxcom media contacts ian stone   david schull   source ambrx related links httpwwwambrxcom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jun    et preview ambrx names dr tiecheng qiao as ceo dr feng tian as cso may    et preview ambrx initiates collaboration with bristolmyers squibb for discovery development of nextgeneration antibody drug conjugates my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search   peter kiener  medimmune  inc  zoominfocom nkt therapeutics inc  peter a kiener precisely targeting the interface between innate and adaptive immunity  home company management team robert mashal robert schaub ron goldstein board of directors robert mashal david hung dan petree michael ross scientific advisory board peter cresswell jenny gumperz david hafler peter kiener mitchell kronenberg alem truneh brian wilson investors sv lifesciences medimmune ventures news nktt granted fast track designation nktt presents data at the  fscdr meeting nktt presents data at the  aacr annual meeting nktt presents data at the  ash annual meeting nktt presents data at  national scd meeting nktt announces preclinical data at ash  biowa and nktt announce licensing of biowas potelligent� technology selexis and nkt therapeutics enter into agreement nkt therapeutics broadens scientific advisory board contact us dr kiener is currently chief scientific officer of ambrx  dr kieners most recent position was ceo of zyngenia  prior to that dr kiener was at astrazeneca plcmedimmune llc as executive vice president and global head of biologics rd  during eight years at medimmune as executive vice president and head of research and development dr kiener helped build industryleading protein and antibody engineering capabilities and oversaw the submission of multiple inds and ndas    dr kiener was also responsible for the integration of both the proteinantibody engineering company cambridge antibody technology and the bcell biologics company cellective therapeutics into medimmune prior to working at medimmune he spent  years at bristolmyers squibb ten of which were spent working on biological therapeutics   during his tenure at medimmune dr kiener was also a member of the medimmune ventures investment committee and was actively involved in growing the organization�s venture portfolio dr kiener previously served on three boards of directors receptor biologix synovex inc and virdante pharmaceuticals he currently serves on the scientific advisory boards of kai genocea nkt therapeutics and vlst inc  dr kiener received his ba in chemistry from the university of lancaster uk and his d phil in biochemistry from oxford university uk   dr kiener has published more than  papers in peerreviewed journals and is an inventor on more than  patents and patent applications powered by tucanwebworld from tucan technologies kiener peter a  insider stock trading  openinsider sector all sectors group by sector aerospace agriculture automobile building business services chemical electrical energy fashion financial food  beverage fund healthcare household insurance machinery media metals mining other personal services real estate retail technology telecom transportation utility industry all industries group by industry insiders filings all purchases sales cik   address  king farm blvd suite  rockville md   results links secyahoogooglefinviztradingviewstockchartsstocktwitsdownload csv tc stat stk ins fil d w m q h y avg filing date t date ticker issuerinc sector indindustry owner ost rel title t tval price l qty oc own h ry ry rm rm rw rw rd rd fd fw fm fm fm fy  medimedimmune inc dedehealthbioprdbiological products no diagkiener peter amdosvpresemd  medimedimmune inc dedehealthbioprdbiological products no diagkiener peter amdosvpresesd dderivative transaction in filing usually option exercise mmultiple transactions in filing earliest reported transaction date and weighted average transaction price aamended filing eerror detected in filing s  salesale of securities on an exchange or to another person s  saleoesale of securities on an exchange or to another person after option exercise f  taxpayment of exercise price or tax liability using portion of securities received from the company p  purchasepurchase of securities on an exchange or from another person return to top contact copyright   openinsidercom all rights reserved